AR040403A1 - Derivados de morfolina antagonista de ccr3 - Google Patents
Derivados de morfolina antagonista de ccr3Info
- Publication number
- AR040403A1 AR040403A1 AR20030101081A ARP030101081A AR040403A1 AR 040403 A1 AR040403 A1 AR 040403A1 AR 20030101081 A AR20030101081 A AR 20030101081A AR P030101081 A ARP030101081 A AR P030101081A AR 040403 A1 AR040403 A1 AR 040403A1
- Authority
- AR
- Argentina
- Prior art keywords
- methyl
- dichlorobenzyl
- morpholin
- urea
- ylmethyl
- Prior art date
Links
- -1 CCR3 ANTAGONIST MORPHOLINE DERIVATIVES Chemical class 0.000 title abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 4
- 239000001257 hydrogen Substances 0.000 abstract 4
- 229910052739 hydrogen Inorganic materials 0.000 abstract 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 3
- 125000004312 morpholin-2-yl group Chemical group [H]N1C([H])([H])C([H])([H])OC([H])(*)C1([H])[H] 0.000 abstract 3
- 125000006512 3,4-dichlorobenzyl group Chemical group [H]C1=C(Cl)C(Cl)=C([H])C(=C1[H])C([H])([H])* 0.000 abstract 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- XLUKYSBCGPFVOU-UHFFFAOYSA-N 1-[(5-amino-1-phenylpyrazol-4-yl)methyl]-3-[[4-[(3,4-dichlorophenyl)methyl]morpholin-2-yl]methyl]urea Chemical compound C1=NN(C=2C=CC=CC=2)C(N)=C1CNC(=O)NCC(OCC1)CN1CC1=CC=C(Cl)C(Cl)=C1 XLUKYSBCGPFVOU-UHFFFAOYSA-N 0.000 abstract 1
- CHFLRXHBQCODJY-ZDUSSCGKSA-N 1-[[(2s)-4-[(3,4-dichlorophenyl)methyl]morpholin-2-yl]methyl]-3-(1,3-thiazol-2-ylmethyl)urea Chemical compound C1=C(Cl)C(Cl)=CC=C1CN1C[C@H](CNC(=O)NCC=2SC=CN=2)OCC1 CHFLRXHBQCODJY-ZDUSSCGKSA-N 0.000 abstract 1
- JZBGNRGEOVQVEE-LBPRGKRZSA-N 1-[[(2s)-4-[(3,4-dichlorophenyl)methyl]morpholin-2-yl]methyl]-3-[(2-methyltetrazol-5-yl)methyl]urea Chemical compound CN1N=NC(CNC(=O)NC[C@@H]2OCCN(CC=3C=C(Cl)C(Cl)=CC=3)C2)=N1 JZBGNRGEOVQVEE-LBPRGKRZSA-N 0.000 abstract 1
- SOANXCFVMUFQHE-AWEZNQCLSA-N 1-[[(2s)-4-[(3,4-dichlorophenyl)methyl]morpholin-2-yl]methyl]-3-[(4-methyl-1,3-thiazol-2-yl)methyl]urea Chemical compound CC1=CSC(CNC(=O)NC[C@@H]2OCCN(CC=3C=C(Cl)C(Cl)=CC=3)C2)=N1 SOANXCFVMUFQHE-AWEZNQCLSA-N 0.000 abstract 1
- JLJGCRRYIYNEQJ-FQEVSTJZSA-N 1-[[(2s)-4-[(3,4-dichlorophenyl)methyl]morpholin-2-yl]methyl]-3-[[3-(4-methoxyphenyl)-1,2-oxazol-5-yl]methyl]urea Chemical compound C1=CC(OC)=CC=C1C1=NOC(CNC(=O)NC[C@@H]2OCCN(CC=3C=C(Cl)C(Cl)=CC=3)C2)=C1 JLJGCRRYIYNEQJ-FQEVSTJZSA-N 0.000 abstract 1
- KMAFRTKBDGSAJJ-IBGZPJMESA-N 1-[[3-(4-chlorophenyl)-1,2-oxazol-5-yl]methyl]-3-[[(2s)-4-[(3,4-dichlorophenyl)methyl]morpholin-2-yl]methyl]urea Chemical compound C1=CC(Cl)=CC=C1C1=NOC(CNC(=O)NC[C@@H]2OCCN(CC=3C=C(Cl)C(Cl)=CC=3)C2)=C1 KMAFRTKBDGSAJJ-IBGZPJMESA-N 0.000 abstract 1
- CHFLRXHBQCODJY-UHFFFAOYSA-N 1-[[4-[(3,4-dichlorophenyl)methyl]morpholin-2-yl]methyl]-3-(1,3-thiazol-2-ylmethyl)urea Chemical compound C1=C(Cl)C(Cl)=CC=C1CN1CC(CNC(=O)NCC=2SC=CN=2)OCC1 CHFLRXHBQCODJY-UHFFFAOYSA-N 0.000 abstract 1
- LJQCWQGMVJGSKQ-UHFFFAOYSA-N 1-[[4-[(3,4-dichlorophenyl)methyl]morpholin-2-yl]methyl]-3-(1h-indol-4-ylmethyl)urea Chemical compound C1=C(Cl)C(Cl)=CC=C1CN1CC(CNC(=O)NCC=2C=3C=CNC=3C=CC=2)OCC1 LJQCWQGMVJGSKQ-UHFFFAOYSA-N 0.000 abstract 1
- YSSDLSCDXACWQT-UHFFFAOYSA-N 1-[[4-[(3,4-dichlorophenyl)methyl]morpholin-2-yl]methyl]-3-(1h-indol-5-ylmethyl)urea Chemical compound C1=C(Cl)C(Cl)=CC=C1CN1CC(CNC(=O)NCC=2C=C3C=CNC3=CC=2)OCC1 YSSDLSCDXACWQT-UHFFFAOYSA-N 0.000 abstract 1
- PHMMAHLAVAGBGI-UHFFFAOYSA-N 1-[[4-[(3,4-dichlorophenyl)methyl]morpholin-2-yl]methyl]-3-(1h-pyrrolo[2,3-b]pyridin-3-ylmethyl)urea Chemical compound C1=C(Cl)C(Cl)=CC=C1CN1CC(CNC(=O)NCC=2C3=CC=CN=C3NC=2)OCC1 PHMMAHLAVAGBGI-UHFFFAOYSA-N 0.000 abstract 1
- YESMWHHSKLCUDO-UHFFFAOYSA-N 1-[[4-[(3,4-dichlorophenyl)methyl]morpholin-2-yl]methyl]-3-(2-thiophen-2-ylethyl)urea Chemical compound C1=C(Cl)C(Cl)=CC=C1CN1CC(CNC(=O)NCCC=2SC=CC=2)OCC1 YESMWHHSKLCUDO-UHFFFAOYSA-N 0.000 abstract 1
- UBRNPKULFLNKTN-UHFFFAOYSA-N 1-[[4-[(3,4-dichlorophenyl)methyl]morpholin-2-yl]methyl]-3-(furan-2-ylmethyl)urea Chemical compound C1=C(Cl)C(Cl)=CC=C1CN1CC(CNC(=O)NCC=2OC=CC=2)OCC1 UBRNPKULFLNKTN-UHFFFAOYSA-N 0.000 abstract 1
- JOAMKEZJIZMCCP-UHFFFAOYSA-N 1-[[4-[(3,4-dichlorophenyl)methyl]morpholin-2-yl]methyl]-3-(pyridin-3-ylmethyl)urea Chemical compound C1=C(Cl)C(Cl)=CC=C1CN1CC(CNC(=O)NCC=2C=NC=CC=2)OCC1 JOAMKEZJIZMCCP-UHFFFAOYSA-N 0.000 abstract 1
- PMMVLXWWCMYNLR-UHFFFAOYSA-N 1-[[4-[(3,4-dichlorophenyl)methyl]morpholin-2-yl]methyl]-3-(thiophen-2-ylmethyl)urea Chemical compound C1=C(Cl)C(Cl)=CC=C1CN1CC(CNC(=O)NCC=2SC=CC=2)OCC1 PMMVLXWWCMYNLR-UHFFFAOYSA-N 0.000 abstract 1
- JZBGNRGEOVQVEE-UHFFFAOYSA-N 1-[[4-[(3,4-dichlorophenyl)methyl]morpholin-2-yl]methyl]-3-[(2-methyltetrazol-5-yl)methyl]urea Chemical compound CN1N=NC(CNC(=O)NCC2OCCN(CC=3C=C(Cl)C(Cl)=CC=3)C2)=N1 JZBGNRGEOVQVEE-UHFFFAOYSA-N 0.000 abstract 1
- ZALONBKTWCFUDD-UHFFFAOYSA-N 1-[[4-[(3,4-dichlorophenyl)methyl]morpholin-2-yl]methyl]-3-[(3-methoxy-1,2-thiazol-5-yl)methyl]urea Chemical compound S1N=C(OC)C=C1CNC(=O)NCC1OCCN(CC=2C=C(Cl)C(Cl)=CC=2)C1 ZALONBKTWCFUDD-UHFFFAOYSA-N 0.000 abstract 1
- SOANXCFVMUFQHE-UHFFFAOYSA-N 1-[[4-[(3,4-dichlorophenyl)methyl]morpholin-2-yl]methyl]-3-[(4-methyl-1,3-thiazol-2-yl)methyl]urea Chemical compound CC1=CSC(CNC(=O)NCC2OCCN(CC=3C=C(Cl)C(Cl)=CC=3)C2)=N1 SOANXCFVMUFQHE-UHFFFAOYSA-N 0.000 abstract 1
- PONVDQFSFUCTIN-UHFFFAOYSA-N 1-[[4-[(3,4-dichlorophenyl)methyl]morpholin-2-yl]methyl]-3-[(6-methoxypyridin-3-yl)methyl]urea Chemical compound C1=NC(OC)=CC=C1CNC(=O)NCC1OCCN(CC=2C=C(Cl)C(Cl)=CC=2)C1 PONVDQFSFUCTIN-UHFFFAOYSA-N 0.000 abstract 1
- WQNPBIUZGHSLPX-UHFFFAOYSA-N 1-[[4-[(3,4-dichlorophenyl)methyl]morpholin-2-yl]methyl]-3-[[5-[(dimethylamino)methyl]furan-2-yl]methyl]urea Chemical compound O1C(CN(C)C)=CC=C1CNC(=O)NCC1OCCN(CC=2C=C(Cl)C(Cl)=CC=2)C1 WQNPBIUZGHSLPX-UHFFFAOYSA-N 0.000 abstract 1
- NYLJYXFMJQIKII-UHFFFAOYSA-N 1-[[4-[(3,4-dichlorophenyl)methyl]morpholin-2-yl]methyl]-3-[[5-[(dimethylamino)methyl]thiophen-2-yl]methyl]urea Chemical compound S1C(CN(C)C)=CC=C1CNC(=O)NCC1OCCN(CC=2C=C(Cl)C(Cl)=CC=2)C1 NYLJYXFMJQIKII-UHFFFAOYSA-N 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 1
- 229960003966 nicotinamide Drugs 0.000 abstract 1
- 235000005152 nicotinamide Nutrition 0.000 abstract 1
- 239000011570 nicotinamide Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D217/06—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
Reivindicación 1: Un compuesto de fórmula (1) en la que: R1 representa heteroarilo substituido o no substituido; Y representa -(CRnaRnb)n-; Rna y Rnb son cada uno independientemente hidrógeno o alquilo C1-6; n es un número entero de 0 a 5; R2 representa arilo substituido o no substituido o heteroarilo substituido o no substituido; cada uno de R3 y R4 representan independientemente hidrógeno o alquilo C1-6; R7 representa hidrógeno o alquilo C1-6; R8 representa hidrógeno o alquilo C1-6; y sales y solvatos de los mismos; con la condición de que se excluyan los siguientes compuestos; N-{[4-(3,4-diclorobencil)morfolin-2-il]metil}-N'-(piridin-3-ilmetil)urea; N-{[4-(3,4-diclorobencil)morfolin-2-il]metil)-N'-[(6-metoxipiridin-3--il)metil]urea; 5-({[({[4-(3,4-diclorobencil)morfolin-2-il]metil}amino)carbonil]-amino}metil)nicotinamida; N-{[4-(3,4-diclorobencil)morfolin-2-il]metil}-N'-(1H-indol-5-ilmetil)urea; N-{[4-(3,4-diclorobencil)morfolin-2-il]metil}-N'-(1H-indol-4-ilmetil)urea; N-{(4-(3,4-diclorobencil)morfolin-2-il]metil}-N'-[(5-metilisoxazol-3-il)metil]urea; N-{[4-(3,4-diclorobencil)morfolin-2-il]metil}-N'-(tien-2-ilmetil)urea; N-{[4-(3,4-diclorobencil)morfolin-2-il]metil}-N'-(2-tien-2-iletil)urea; N-{[4-(3,4-diclorobencil)morfolin-2-il]metil}-N'-({5-[(dimetilamino)metil]-2-furil}metil)urea; N-{[4-(3,4-diclorobencil)morfolin-2-il]metil}-N'-[(3-metoxiisotiazol-5-il)metil]urea; N-{[4-(3,4-diclorobencil)morfolin-2-il]metil}-N'-[(4-metil-1,3-tiazol-2-il)metil]urea; N-{[4-(3,4-diclorobencil)morfolin-2-il]metil}-N'-(1,3-tiazol-2-ilmetil)urea; N-{[4-3,4-diclorobencil)morfolin-2-il]metil}-N'-[(2-metil-1,3-tiazol-4-il)metil]urea; 2-({[({[4-(3,4-diclorobencil)morfolin-2-il]metil}amin)carbonil]-amino}-metil)-4-metil-1,3-tiazolo-5-carboxilato de metilo; N-[(5-amino-1-fenil-1H-pirazol-4-il)metil]-N'-{[4-(3,4-diclorobencil)-morfolin-2-il]metil}urea; N-{[4-(3,4-diclorobencil)morfolin-2-il]metil}-N'-(1H-pirrolo[2,3-b]piridin-3-ilmetil)urea; N-{[4-(3,4-diclorobencil)morfolin-2-il]metil}-N'-({5-[(dimetilamino)-metil]tien-2-il}metil)urea; N-{[4-(3,4-diclorobencil)morfolin-2-il]metil}-N'-(2-furilmetil)urea; N-{[4-(3,4-diclorobencil)morfolin-2-il]metil}-N'-[(2-metil-2H-tetrazol--5-il)metil]urea; N-{[3-(4-clorofenil)isoxazol-5-il]metil}-N'-{[(2S)-4-(3,4-diclorobencil)-morfolin-2-il]metil}urea; N-{[(2S)-4-(3,4-diclorobencil)morfolin-2-il]metil}-N'-[(2-metil-2H-tetrazol-5-il)metil]urea; N-{[(2S)-4-(3,4-diclorobencil)morfolin-2-il]metil}-N'-[(4-metil-1,3-tiazol-2-il)metil]urea; N-{[(2S)-4-(3,4-diclorobencil)morfolin-2-il]metil}-N'-(1,3-tiazol-2-ilmetil)-urea; y N-{[(2S)-4-(3,4-diclorobencil)morfolin-2-il]metil}-N'-{[3-(4-metoxifenil)-isoxazol-5-il]metil}urea.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0207434A GB0207434D0 (en) | 2002-03-28 | 2002-03-28 | Novel compounds |
| GB0301608A GB0301608D0 (en) | 2003-01-24 | 2003-01-24 | Novel compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR040403A1 true AR040403A1 (es) | 2005-04-06 |
Family
ID=28676494
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AR20030101081A AR040403A1 (es) | 2002-03-28 | 2003-03-27 | Derivados de morfolina antagonista de ccr3 |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US7622464B2 (es) |
| EP (1) | EP1487828B1 (es) |
| JP (1) | JP4465195B2 (es) |
| KR (1) | KR20040093488A (es) |
| CN (1) | CN1656092A (es) |
| AR (1) | AR040403A1 (es) |
| AT (1) | ATE413399T1 (es) |
| AU (1) | AU2003226757A1 (es) |
| BR (1) | BR0308780A (es) |
| CA (1) | CA2480106A1 (es) |
| CY (1) | CY1108652T1 (es) |
| DE (1) | DE60324535D1 (es) |
| DK (1) | DK1487828T3 (es) |
| ES (1) | ES2315519T3 (es) |
| IL (1) | IL164047A0 (es) |
| IS (1) | IS7444A (es) |
| MX (1) | MXPA04009459A (es) |
| NO (1) | NO20044448L (es) |
| PT (1) | PT1487828E (es) |
| RU (1) | RU2004127928A (es) |
| SI (1) | SI1487828T1 (es) |
| TW (1) | TW200400035A (es) |
| WO (1) | WO2003082861A2 (es) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7399866B2 (en) | 2003-01-14 | 2008-07-15 | Cytokinetics, Inc. | Compounds, compositions, and methods |
| WO2004089296A2 (en) | 2003-04-03 | 2004-10-21 | The Regents Of The University Of California | Improved inhibitors for the soluble epoxide hydrolase |
| CA2559665A1 (en) | 2004-03-16 | 2005-09-29 | The Regents Of The University Of California | Reducing nephropathy with inhibitors of soluble epoxide hydrolase and epoxyeicosanoids |
| CN101035525A (zh) | 2004-06-17 | 2007-09-12 | 赛特凯恩蒂克公司 | 用于治疗心脏疾病的经取代的脲衍生物 |
| EP2292272A3 (en) * | 2004-07-08 | 2011-10-26 | Novo Nordisk A/S | Polypeptide protracting tags comprising a tetrazole moiety |
| US7176222B2 (en) | 2004-07-27 | 2007-02-13 | Cytokinetics, Inc. | Syntheses of ureas |
| DK1801108T3 (da) | 2004-09-08 | 2013-02-18 | Mitsubishi Tanabe Pharma Corp | Morpholinforbindelser til behandling af inflammationer. |
| CN101084216B (zh) | 2004-10-20 | 2011-09-14 | 加利福尼亚大学董事会 | 可溶性环氧化物水解酶的改进抑制剂 |
| US7538223B2 (en) | 2005-08-04 | 2009-05-26 | Cytokinetics, Inc. | Compounds, compositions and methods |
| AR058347A1 (es) | 2005-12-15 | 2008-01-30 | Cytokinetics Inc | Entidades quimias composiciones y metodos |
| US7825120B2 (en) | 2005-12-15 | 2010-11-02 | Cytokinetics, Inc. | Certain substituted ((piperazin-1-ylmethyl)benzyl)ureas |
| WO2007078815A2 (en) | 2005-12-16 | 2007-07-12 | Cytokinetics, Inc. | Certain chemical entities, compositions, and methods |
| US7989455B2 (en) | 2005-12-19 | 2011-08-02 | Cytokinetics, Inc. | Compounds, compositions and methods |
| AR059826A1 (es) | 2006-03-13 | 2008-04-30 | Univ California | Inhibidores de urea conformacionalmente restringidos de epoxido hidrolasa soluble |
| EP2182809B1 (en) | 2007-08-27 | 2018-01-17 | Dart Neuroscience (Cayman) Ltd | Therapeutic isoxazole compounds |
| WO2012054093A2 (en) | 2010-01-29 | 2012-04-26 | The Regents Of The University Of California | Acyl piperidine inhibitors of soluble epoxide hydrolase |
| RU2512293C1 (ru) * | 2012-12-13 | 2014-04-10 | Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Ярославский государственный технический университет" | Способ получения этил 1,2,4-оксадиазол-5-карбоксилатов |
| CN107362362B (zh) * | 2017-07-20 | 2019-01-01 | 复旦大学 | Sirt1抑制剂在预防和治疗放射引起的肠道疾病中的应用 |
| US20230271983A1 (en) * | 2020-07-29 | 2023-08-31 | Universidade De Santiago De Compostela | Functionalized isonitriles and products, preparation and uses thereof |
| WO2022031735A1 (en) * | 2020-08-03 | 2022-02-10 | Global Blood Therapeutics, Inc. | Urea derivatives as pyruvate kinase activators |
| CN119330881A (zh) * | 2024-09-06 | 2025-01-21 | 苏州汉德创宏生化科技有限公司 | 一种3-氨甲基-1-h吡唑的合成方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4851526A (en) | 1987-09-04 | 1989-07-25 | Schering A.G. | 1-(4-Substituted phenyl)-1H-imidazoles compounds |
| JP3087763B2 (ja) | 1990-11-30 | 2000-09-11 | 三井化学株式会社 | 新規な複素環式化合物およびそれを含有する医薬組成物 |
| US5219856A (en) | 1992-04-06 | 1993-06-15 | E. I. Du Pont De Nemours And Company | Angiotensin-II receptor blocking, heterocycle substituted imidazoles |
| WO1995032196A1 (en) | 1994-05-19 | 1995-11-30 | Merck Sharp & Dohme Limited | Piperazine, piperidine and tetrahydropyridine derivatives of indol-3-ylalkyl as 5-ht1d-alpha agonists |
| AU702307B2 (en) | 1994-07-20 | 1999-02-18 | Altana Pharma Ag | Piperazinothiopyridines for the control of helicobater bacteria |
| US5654316A (en) | 1995-06-06 | 1997-08-05 | Schering Corporation | Piperidine derivatives as neurokinin antagonists |
| AU2980797A (en) | 1996-06-11 | 1998-01-07 | Yoshitomi Pharmaceutical Industries, Ltd. | Fused heterocyclic compounds and medicinal uses thereof |
| US5919776A (en) * | 1996-12-20 | 1999-07-06 | Merck & Co., Inc. | Substituted aminoquinolines as modulators of chemokine receptor activity |
| US6207665B1 (en) | 1997-06-12 | 2001-03-27 | Schering Aktiengesellschaft | Piperazine derivatives and their use as anti-inflammatory agents |
| IT1293807B1 (it) | 1997-08-01 | 1999-03-10 | Recordati Chem Pharm | Derivati 1- (n-fenilaminoalchil) piperazinici sostituiti alla posizione 2 dell'anello fenilico |
| US6031097A (en) | 1997-10-27 | 2000-02-29 | Neurogen Corporation | 1-(N-(arylalkylaminoalkyl) aminoisoquinolines; a new class of dopamine receptor subtype specific ligands |
| WO1999021848A2 (en) | 1997-10-27 | 1999-05-06 | Neurogen Corporation | Novel 1-(n'-(arylalkylaminoalkyl))aminoisoindoles; a new class of dopamine receptor subtype specific ligands |
| EP1117663A2 (en) | 1998-09-30 | 2001-07-25 | Neurogen Corporation | 2-piperazino alkylamino benzoazole derivatives: dopamine receptor subtype specific ligands |
| ES2527688T3 (es) | 2000-09-29 | 2015-01-28 | Glaxo Group Limited | Derivados de morfolin-acetamida para el tratamiento de enfermedades inflamatorias |
| HUP0303107A2 (hu) * | 2000-09-29 | 2004-03-01 | Glaxo Group Ltd. | Gyulladásos betegségek kezelésére alkalmazható vegyületek, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények |
-
2003
- 2003-03-26 TW TW092106766A patent/TW200400035A/zh unknown
- 2003-03-27 WO PCT/EP2003/003335 patent/WO2003082861A2/en not_active Ceased
- 2003-03-27 CN CNA038115506A patent/CN1656092A/zh active Pending
- 2003-03-27 ES ES03745294T patent/ES2315519T3/es not_active Expired - Lifetime
- 2003-03-27 JP JP2003580326A patent/JP4465195B2/ja not_active Expired - Lifetime
- 2003-03-27 BR BR0308780-8A patent/BR0308780A/pt not_active Application Discontinuation
- 2003-03-27 IL IL16404703A patent/IL164047A0/xx unknown
- 2003-03-27 AR AR20030101081A patent/AR040403A1/es unknown
- 2003-03-27 AU AU2003226757A patent/AU2003226757A1/en not_active Abandoned
- 2003-03-27 KR KR10-2004-7015398A patent/KR20040093488A/ko not_active Withdrawn
- 2003-03-27 CA CA002480106A patent/CA2480106A1/en not_active Abandoned
- 2003-03-27 PT PT03745294T patent/PT1487828E/pt unknown
- 2003-03-27 RU RU2004127928/04A patent/RU2004127928A/ru not_active Application Discontinuation
- 2003-03-27 AT AT03745294T patent/ATE413399T1/de active
- 2003-03-27 US US10/509,162 patent/US7622464B2/en active Active
- 2003-03-27 DK DK03745294T patent/DK1487828T3/da active
- 2003-03-27 SI SI200331471T patent/SI1487828T1/sl unknown
- 2003-03-27 MX MXPA04009459A patent/MXPA04009459A/es unknown
- 2003-03-27 DE DE60324535T patent/DE60324535D1/de not_active Expired - Lifetime
- 2003-03-27 EP EP03745294A patent/EP1487828B1/en not_active Expired - Lifetime
-
2004
- 2004-09-13 IS IS7444A patent/IS7444A/is unknown
- 2004-10-19 NO NO20044448A patent/NO20044448L/no not_active Application Discontinuation
-
2008
- 2008-12-19 CY CY20081101474T patent/CY1108652T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RU2004127928A (ru) | 2005-06-27 |
| JP4465195B2 (ja) | 2010-05-19 |
| IL164047A0 (en) | 2005-12-18 |
| KR20040093488A (ko) | 2004-11-05 |
| AU2003226757A1 (en) | 2003-10-13 |
| MXPA04009459A (es) | 2005-01-25 |
| JP2005526815A (ja) | 2005-09-08 |
| NO20044448L (no) | 2004-10-26 |
| PT1487828E (pt) | 2009-01-06 |
| DE60324535D1 (de) | 2008-12-18 |
| ATE413399T1 (de) | 2008-11-15 |
| US20060063765A1 (en) | 2006-03-23 |
| EP1487828A2 (en) | 2004-12-22 |
| EP1487828B1 (en) | 2008-11-05 |
| WO2003082861A2 (en) | 2003-10-09 |
| US7622464B2 (en) | 2009-11-24 |
| DK1487828T3 (da) | 2009-02-02 |
| CY1108652T1 (el) | 2014-08-13 |
| IS7444A (is) | 2004-09-13 |
| TW200400035A (en) | 2004-01-01 |
| ES2315519T3 (es) | 2009-04-01 |
| CN1656092A (zh) | 2005-08-17 |
| CA2480106A1 (en) | 2003-10-09 |
| WO2003082861A3 (en) | 2004-03-11 |
| BR0308780A (pt) | 2004-12-28 |
| SI1487828T1 (sl) | 2009-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR040403A1 (es) | Derivados de morfolina antagonista de ccr3 | |
| RU2416603C2 (ru) | Производные аминодигидротиазина | |
| RU2348625C2 (ru) | Энантиомеры производных тиофенгидроксамовой кислоты и их применение в качестве ингибиторов гдац | |
| RU2202543C2 (ru) | Производные 2-(иминометил)аминофенила, способы их получения, соединения, фармацевтическая композиция | |
| BRPI0213243B8 (pt) | composto heterocíclico aromático contendo um anel oxazol, tiazol ou imidazol, ou um sal farmaceuticamente aceitável do mesmo, e, composição farmacêutica | |
| CA2396824A1 (en) | Heteroaromatic carboxamide derivatives and their use as inhibitors of the enzyme ikk-2 | |
| PE20030968A1 (es) | Derivados de 5-feniltiazol como inhibidores de cinasas | |
| NO20074296L (no) | 4-cyklopropyl-1,2,3-tiadiazolforbindelse, agrohortikulturelt plantesykdoms-kontrollmiddel og fremgangsmate for anvendelse av det samme | |
| RU2006123559A (ru) | Биарилсульфонамиды в качестве ммр-ингибиторов | |
| DE60137405D1 (de) | Isoxazol- und thiazolverbindungen und ihre verwendung als medikamente | |
| JP2005533004A5 (es) | ||
| RU2003103767A (ru) | Производные оксазолидинона в качестве противомикробных препаратов | |
| JP2005511746A5 (es) | ||
| RU2004130280A (ru) | Замещенные индазолы, обладающие притовораковой активностью | |
| RU2010126105A (ru) | Производные пиридина, замещенные гетероциклическим кольцом и фосфоноксиметильной группой, и содержащие их противогрибковые средства | |
| NZ229266A (en) | Compositions containing arylmethylene-substituted thiazolidinone, imidazolidinone and oxazolidinone derivatives and sulphur analogues (thiones) | |
| NO20081464L (no) | 1-heterocyklusulfonyl, 2-aminometyl, 5-(hetero-)aryl subsidiert 1-H-pyrrol-derivater som syresekresjonsinhibitorer | |
| JP2003534336A5 (es) | ||
| PE20040649A1 (es) | Procedimiento para la preparacion de benzoilureas heterociclicamente sustituidas | |
| RU2005133994A (ru) | Оксимные производные и их применение в качестве фармацевтически активных агентов | |
| PE20091952A1 (es) | Compuestos de tiazole y oxazole de sulfonamida de benzeno | |
| PE20060855A1 (es) | Derivados de carboxamida biciclicos fusionados como inhibidores de cxcr2 | |
| NZ602099A (en) | Stat3 inhibitor containing quinolinecarboxamide derivative as active ingredient | |
| PE20000061A1 (es) | Derivados de tiazol | |
| RU2010142229A (ru) | Производное циклопентилакриламида |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |